Details of the Drug

General Information of Drug (ID: DMU1XOD)

Drug Name
Nafamostat
Synonyms
FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum
Indication
Disease Entry ICD 11 Status REF
Pancreatitis DC31-DC34 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [2]
Sepsis 1G40-1G41 Discontinued in Phase 2 [3]
Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [4]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 347.4
Logarithm of the Partition Coefficient (xlogp) 2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 81.96 mL/min/kg [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.84 hours [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 5.71 L/kg [5]
Chemical Identifiers
Formula
C19H17N5O2
IUPAC Name
(6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate
Canonical SMILES
C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N
InChI
InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
InChIKey
MQQNFDZXWVTQEH-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4413
ChEBI ID
CHEBI:135466
CAS Number
81525-10-2
DrugBank ID
DB12598
TTD ID
D07XHO
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serine protease unspecific (SP) TTEMV5X NOUNIPROTAC Inhibitor [6]
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Not Available [7]
COVID-19 spike glycoprotein (S) TTZ3COY SPIKE_SARS2 Inhibitor [8]
MERS-CoV spike glycoprotein (S) TT85VHW A0A140AYZ5_9BETC Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pancreatitis
ICD Disease Classification DC31-DC34
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tumor necrosis factor (TNF) DTT TNF 8.51E-01 0.05 0.27
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4262).
2 ClinicalTrials.gov (NCT04352400) Efficacy of Nafamostat in Covid-19 Patients (RACONA Study). U.S. National Institutes of Health.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006437)
4 Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20.
7 Clinical pipeline report, company report or official report of AstraZeneca (2009).
8 Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.